Chemocentryx Inc (CCXI) 4.80 $CCXI
What Investors are Making of These Biotech Stocks? - ChemoCentryx, Alder Biopharma, Neothetics, and OvaScience
PR Newswire - Tue Jun 28, 6:40AM CDT
Economic uncertainty and pricing pressures remain the Biotech industry's biggest threats, but despite the challenges, several companies continue to impress. Ahead of today's session, Stock-Callers.com has issued alerts on the following equities: ChemoCentryx Inc. (NASDAQ: CCXI), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Neothetics Inc. (NASDAQ: NEOT), and OvaScience Inc. (NASDAQ: OVAS). Learn more about these stocks and receive your complimentary trade alerts at:
ALDR: 27.00 (+0.42), OVAS: 5.66 (+0.20), NEOT: 1.03 (+0.07), CCXI: 4.80 (-0.02)
ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
GlobeNewswire - Thu Jun 16, 7:30AM CDT
-- Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen --
CCXI: 4.80 (-0.02)
ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for CCX168 for the treatment of ANCA-Associated Vasculitis, or AAV. As described by the EMA, PRIME aims to bring promising innovative medicines to patients faster by optimizing and supporting medicine development. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on clinical data.
CCXI: 4.80 (-0.02)
ChemoCentryx to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed May 25, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 3:30 p.m. ET. The conference will be held at the Grand Hyatt Hotel in New York, NY
CCXI: 4.80 (-0.02)
ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
GlobeNewswire - Mon May 23, 8:15AM CDT
-- Treatment with CCX168 successful in achieving clinical efficacy endpoints while eliminating high-dose oral corticosteroids from current standard-of-care regimen, suggesting a new treatment paradigm for ANCA-Associated Vasculitis --
CCXI: 4.80 (-0.02)
ChemoCentryx Announces Data Presentation of Novel CCR6 Inhibitors at the 2016 Society for Investigative Dermatology (SID) Annual Meeting
GlobeNewswire - Thu May 12, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that preclinical data using a series of orally-available inhibitors of the chemokine receptor known as CCR6, have been selected for a poster presentation at the 2016 Society for Investigational Dermatology Annual Meeting, being held May 11-14, 2016 in Scottsdale, Arizona.
CCXI: 4.80 (-0.02)
Can The Uptrend Continue for ChemoCentryx (CCXI)?
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:32AM CDT
Investors certainly have to be happy with ChemoCentryx, Inc. (CCXI) and its short term performance
CCXI: 4.80 (-0.02)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 42.4%
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:39AM CDT
ChemoCentryx, Inc. (CCXI) shares rose over 42% in the last trading session.
CCXI: 4.80 (-0.02), AAAP: 30.72 (unch)
ChemoCentryx to Host R&D Day on May 18, 2016
GlobeNewswire - Wed May 11, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company will host an R&D Day on Wednesday, May 18, 2016 at 12:00 p.m. Eastern Time in New York, NY. The Company will be joined by several leading physicians.
CCXI: 4.80 (-0.02)
ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 10, 6:07AM CDT
- Company Announces Exclusive License Agreement with Vifor Pharma to Commercialize Orally Administered Complement 5a Receptor Inhibitor CCX168 in Europe and Certain Other Markets; Agreement Includes $85 Million Upfront, Comprising $60 Million in Cash in Addition to $25 Million Equity Investment -
CCXI: 4.80 (-0.02)
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
GlobeNewswire - Tue May 10, 6:07AM CDT
- Vifor Pharma to market drug in selected territories outside the US, ChemoCentryx responsible for worldwide development of CCX168 -
CCXI: 4.80 (-0.02)
ChemoCentryx to Hold First Quarter 2016 Financial Results Conference Call on Tuesday, May 10, 2016
GlobeNewswire - Thu May 05, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's first quarter 2016 financial results will be released before market open on Tuesday, May 10, 2016. ChemoCentryx executive management will host a conference call beginning at 8:30 a.m. Eastern Time on May 10, 2016, to discuss these results and to answer questions.
CCXI: 4.80 (-0.02)
ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis
GlobeNewswire - Thu Apr 28, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Company a one-year grant of $500,000 to assist in the clinical development of CCX168, the Company's lead drug candidate for the treatment of patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, or AAV. CCX168 is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.
CCXI: 4.80 (-0.02)
Global Anca Vasculitis Pipeline Review 2016 Featuring ChemoCentryx, Inc., GlaxoSmithKline Plc & Kineta, Inc. - Research and Markets
BusinessWire - Wed Apr 20, 9:17AM CDT
Research and Markets has announced the addition of the "Anca Vasculitis - Pipeline Review, H1 2016" report to their offering.
CCXI: 4.80 (-0.02), GSK: 43.57 (+0.19)
ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Mon Apr 18, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced the presentation of data from its immuno-oncology program at the American Association for Cancer Research (AACR) 2016 Annual Meeting, being held April 16-20, 2016 in New Orleans, Louisiana. The preclinical data highlight the synergistic effect of employing an antibody against the checkpoint inhibitor PD-L1 in conjunction with CCX9588, in a model of triple negative breast cancer. CCX9588 is a small molecule inhibitor of the chemokine receptor known as CCR1 and is currently in preclinical development for certain oncology indications targeting both solid and liquid tumors.
CCXI: 4.80 (-0.02)
ChemoCentryx Reports Fourth Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Mon Mar 14, 6:17PM CDT
-- Successful Phase II 'CLEAR' Clinical Trial Demonstrated Rapid Onset of Benefit While Eliminating Need for Chronic High-Dose Steroids in ANCA-Associated Vasculitis (AAV) With Complement Inhibitor CCX168 --
CCXI: 4.80 (-0.02)
ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:45AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise over 8% on the day.
CCXI: 4.80 (-0.02), PETX: 7.00 (+0.31)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 30.04 (+0.46), AMGN: 161.00 (-0.10), AMPE: 1.09 (-0.06), LLY: 79.65 (-0.01), ENZ: 5.94 (-0.05), CCXI: 4.80 (-0.02), ABBV: 64.50 (+0.34), ARNA: 1.70 (+0.06), CELGZ: 1.43 (+0.08)
Ulcerative Colitis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 9:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/9fz45l/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4D Pharma Plc - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - Atlantic Healthcare Plc - Avaxia Biologics, Inc. - BioAtla, LLC - BioLineRx, Ltd. - Bionovis SA - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Effimune SAS - Eli Lilly and Company - Emergent BioSolutions Inc. - (50 Others) For more information visit http://www.researchandmarkets.com/research/9fz45l/ulcerative
EBS: 30.04 (+0.46), CCXI: 4.80 (-0.02), AMGN: 161.00 (-0.10), LLY: 79.65 (-0.01), ARNA: 1.70 (+0.06), CELGZ: 1.43 (+0.08)
Nephropathy Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq5b5l/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Nephropathy Overview - Therapeutics Development - Pipeline Products for Nephropathy - Overview - Pipeline Products for Nephropathy - Comparative Analysis - Nephropathy - Therapeutics under Development by Companies - Nephropathy - Therapeutics under Investigation by Universities/Institutes - Nephropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Nephropathy - Products under Development by Companies - Nephropathy - Products under Investigation by Universities/Institutes - Nephropathy - Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - ChemoCentryx, Inc. - Complexa, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/hq...ephropathy
ANTH: 3.85 (+0.04), CCXI: 4.80 (-0.02)
What Investors are Making of These Biotech Stocks? - ChemoCentryx, Alder Biopharma, Neothetics, and OvaScience
PR Newswire - Tue Jun 28, 6:40AM CDT
Economic uncertainty and pricing pressures remain the Biotech industry's biggest threats, but despite the challenges, several companies continue to impress. Ahead of today's session, Stock-Callers.com has issued alerts on the following equities: ChemoCentryx Inc. (NASDAQ: CCXI), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Neothetics Inc. (NASDAQ: NEOT), and OvaScience Inc. (NASDAQ: OVAS). Learn more about these stocks and receive your complimentary trade alerts at:
ALDR: 27.00 (+0.42), OVAS: 5.66 (+0.20), NEOT: 1.03 (+0.07), CCXI: 4.80 (-0.02)
ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
GlobeNewswire - Thu Jun 16, 7:30AM CDT
-- Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen --
CCXI: 4.80 (-0.02)
ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for CCX168 for the treatment of ANCA-Associated Vasculitis, or AAV. As described by the EMA, PRIME aims to bring promising innovative medicines to patients faster by optimizing and supporting medicine development. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on clinical data.
CCXI: 4.80 (-0.02)
ChemoCentryx to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed May 25, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 3:30 p.m. ET. The conference will be held at the Grand Hyatt Hotel in New York, NY
CCXI: 4.80 (-0.02)
ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
GlobeNewswire - Mon May 23, 8:15AM CDT
-- Treatment with CCX168 successful in achieving clinical efficacy endpoints while eliminating high-dose oral corticosteroids from current standard-of-care regimen, suggesting a new treatment paradigm for ANCA-Associated Vasculitis --
CCXI: 4.80 (-0.02)
ChemoCentryx Announces Data Presentation of Novel CCR6 Inhibitors at the 2016 Society for Investigative Dermatology (SID) Annual Meeting
GlobeNewswire - Thu May 12, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that preclinical data using a series of orally-available inhibitors of the chemokine receptor known as CCR6, have been selected for a poster presentation at the 2016 Society for Investigational Dermatology Annual Meeting, being held May 11-14, 2016 in Scottsdale, Arizona.
CCXI: 4.80 (-0.02)
Can The Uptrend Continue for ChemoCentryx (CCXI)?
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:32AM CDT
Investors certainly have to be happy with ChemoCentryx, Inc. (CCXI) and its short term performance
CCXI: 4.80 (-0.02)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 42.4%
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:39AM CDT
ChemoCentryx, Inc. (CCXI) shares rose over 42% in the last trading session.
CCXI: 4.80 (-0.02), AAAP: 30.72 (unch)
ChemoCentryx to Host R&D Day on May 18, 2016
GlobeNewswire - Wed May 11, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company will host an R&D Day on Wednesday, May 18, 2016 at 12:00 p.m. Eastern Time in New York, NY. The Company will be joined by several leading physicians.
CCXI: 4.80 (-0.02)
ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 10, 6:07AM CDT
- Company Announces Exclusive License Agreement with Vifor Pharma to Commercialize Orally Administered Complement 5a Receptor Inhibitor CCX168 in Europe and Certain Other Markets; Agreement Includes $85 Million Upfront, Comprising $60 Million in Cash in Addition to $25 Million Equity Investment -
CCXI: 4.80 (-0.02)
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
GlobeNewswire - Tue May 10, 6:07AM CDT
- Vifor Pharma to market drug in selected territories outside the US, ChemoCentryx responsible for worldwide development of CCX168 -
CCXI: 4.80 (-0.02)
ChemoCentryx to Hold First Quarter 2016 Financial Results Conference Call on Tuesday, May 10, 2016
GlobeNewswire - Thu May 05, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's first quarter 2016 financial results will be released before market open on Tuesday, May 10, 2016. ChemoCentryx executive management will host a conference call beginning at 8:30 a.m. Eastern Time on May 10, 2016, to discuss these results and to answer questions.
CCXI: 4.80 (-0.02)
ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis
GlobeNewswire - Thu Apr 28, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has awarded the Company a one-year grant of $500,000 to assist in the clinical development of CCX168, the Company's lead drug candidate for the treatment of patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, or AAV. CCX168 is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR.
CCXI: 4.80 (-0.02)
Global Anca Vasculitis Pipeline Review 2016 Featuring ChemoCentryx, Inc., GlaxoSmithKline Plc & Kineta, Inc. - Research and Markets
BusinessWire - Wed Apr 20, 9:17AM CDT
Research and Markets has announced the addition of the "Anca Vasculitis - Pipeline Review, H1 2016" report to their offering.
CCXI: 4.80 (-0.02), GSK: 43.57 (+0.19)
ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Mon Apr 18, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced the presentation of data from its immuno-oncology program at the American Association for Cancer Research (AACR) 2016 Annual Meeting, being held April 16-20, 2016 in New Orleans, Louisiana. The preclinical data highlight the synergistic effect of employing an antibody against the checkpoint inhibitor PD-L1 in conjunction with CCX9588, in a model of triple negative breast cancer. CCX9588 is a small molecule inhibitor of the chemokine receptor known as CCR1 and is currently in preclinical development for certain oncology indications targeting both solid and liquid tumors.
CCXI: 4.80 (-0.02)
ChemoCentryx Reports Fourth Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Mon Mar 14, 6:17PM CDT
-- Successful Phase II 'CLEAR' Clinical Trial Demonstrated Rapid Onset of Benefit While Eliminating Need for Chronic High-Dose Steroids in ANCA-Associated Vasculitis (AAV) With Complement Inhibitor CCX168 --
CCXI: 4.80 (-0.02)
ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:45AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise over 8% on the day.
CCXI: 4.80 (-0.02), PETX: 7.00 (+0.31)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 30.04 (+0.46), AMGN: 161.00 (-0.10), AMPE: 1.09 (-0.06), LLY: 79.65 (-0.01), ENZ: 5.94 (-0.05), CCXI: 4.80 (-0.02), ABBV: 64.50 (+0.34), ARNA: 1.70 (+0.06), CELGZ: 1.43 (+0.08)
Ulcerative Colitis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 9:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/9fz45l/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4D Pharma Plc - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - Atlantic Healthcare Plc - Avaxia Biologics, Inc. - BioAtla, LLC - BioLineRx, Ltd. - Bionovis SA - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Effimune SAS - Eli Lilly and Company - Emergent BioSolutions Inc. - (50 Others) For more information visit http://www.researchandmarkets.com/research/9fz45l/ulcerative
EBS: 30.04 (+0.46), CCXI: 4.80 (-0.02), AMGN: 161.00 (-0.10), LLY: 79.65 (-0.01), ARNA: 1.70 (+0.06), CELGZ: 1.43 (+0.08)
Nephropathy Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq5b5l/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Nephropathy Overview - Therapeutics Development - Pipeline Products for Nephropathy - Overview - Pipeline Products for Nephropathy - Comparative Analysis - Nephropathy - Therapeutics under Development by Companies - Nephropathy - Therapeutics under Investigation by Universities/Institutes - Nephropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Nephropathy - Products under Development by Companies - Nephropathy - Products under Investigation by Universities/Institutes - Nephropathy - Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - ChemoCentryx, Inc. - Complexa, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/hq...ephropathy
ANTH: 3.85 (+0.04), CCXI: 4.80 (-0.02)
